🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — June 18, 2026

Two micro-cap biotech/life sciences companies received Nasdaq deficiency notices in the same week, signaling a potential sector-wide liquidity and compliance stress among small-cap listed firms. Algorhythm Holdings (RIME) received a bid price deficiency notice on June 16, 2026, with a 180-day cure period through December 14, 2026, and a possible extension, while Dyadic International (DYAI) received a delisting notice on June 18, 2026, after failing to cure its bid price deficiency and also failing to meet alternative continued listing standards (minimum $2.5M shareholders' equity). Both filings carry negative sentiment and high materiality (8/10 and 9/10), but Dyadic's situation is more acute due to the simultaneous failure of multiple listing requirements and the lack of an automatic extension. The clustering of these events suggests that many micro-cap companies are struggling to maintain Nasdaq listing standards amid a challenging capital-raising environment, and investors should monitor for a wave of similar deficiency notices.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — June 18, 2026

The June 18, 2026, digest of 45 SEC filings reveals a period of significant leadership churn, with a notable cluster of CFO departures and appointments across sectors, including Pfizer, Mondelez, and AudioEye. Insider activity is sparse, but the departure of a CFO at MapLight Therapeutics due to a human resources violation and a director resignation at Ulixe Corp. over governance concerns are high-risk flags. Period-over-period comparisons are largely absent from these event-driven filings, limiting trend analysis, but forward-looking data points to a catalyst-rich calendar with new CFOs starting in July and several retirement transitions. Shareholder dissent is a recurring theme, with Match Group's Say-on-Pay proposal failing and several equity plan amendments facing notable opposition, signaling governance risk. Capital allocation is focused on executive retention and incentive programs, as seen at Tyson Foods and Battalion Oil. The most actionable insights stem from the forced CFO departure at MapLight, the governance crisis at Ulixe, and the strategic board appointments at Comstock and Allegro MicroSystems.

45 high priority 45 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 18, 2026

This digest covers 50 filings from June 18, 2026, revealing a pronounced bifurcation in corporate health. A clear theme is the aggressive use of capital markets by distressed companies to stave off insolvency, with 6 at-the-market (ATM) offerings and 3 private placements totaling over $500 million in potential dilution. Conversely, several firms are successfully refinancing debt on favorable terms, extending maturities by 2-4 years and improving balance sheet flexibility. The most critical distress signals are concentrated in micro-cap and pre-revenue biotech/tech companies, with 2 Nasdaq delisting notices (Dyadic International, Algorhythm Holdings) and one terminated SPAC merger (Papaya Growth Opportunity Corp. I). A notable sector theme is the high cost of distress financing, with companies like Nuvve Holding and CoreWeave agreeing to interest rates of 39% and 9.625% respectively, highlighting a two-tiered credit market. Insider trading data was sparse across these filings, but the prevalence of dilutive financing structures (convertible notes, preferred stock exchanges) signals significant shareholder value destruction for existing holders in distressed names.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 18, 2026

The 45 filings for June 18, 2026, reveal a dynamic period for US board rooms, with a high volume of officer and director changes, particularly in the healthcare and technology sectors. A notable trend is the significant number of CFO and COO departures, including at major firms like Pfizer and FIS, often with interim appointments and external searches, signaling potential strategic pivots. Annual meeting results show strong shareholder support for director slates and equity plans, but with pockets of dissent, notably at Match Group where the Say-on-Pay proposal failed, and at Genprex and Zura Bio where significant opposition to equity plan amendments and director elections was recorded. Insider activity is limited, but the departure of MapLight's CFO due to a human resources violation and the resignation of a Ulixe Corp director with concerns about reporting status are material risk flags. Capital allocation actions are sparse, with only Tyson Foods entering a new, highly lucrative employment agreement for its Chairman. The overall sentiment is neutral with mixed pockets, suggesting investors should closely monitor the leadership transitions and shareholder dissent for potential impacts on corporate strategy and governance.

45 high priority 45 total filings
· daily

USA Insider Trading Pulse — June 18, 2026

The June 18, 2026 insider trading pulse reveals a day dominated by routine equity awards and option exercises, which account for over 60% of filings and carry neutral sentiment. However, a clear bearish undercurrent emerges from multiple C-suite and director sales executed under Rule 10b5-1 plans, particularly in the technology and healthcare sectors. Notable insider buying is concentrated in two Chinese education firms, Gaotu Techedu and 51Talk, where CEOs made substantial open-market purchases, signaling strong conviction despite market headwinds. The most significant capital market signal is the $1.78M sale by a Valero Energy SVP, the largest single insider disposition of the day. Overall, the data suggests a cautious posture among corporate insiders, with selling pressure outweighing buying, while routine awards provide a baseline of neutral activity.

49 high priority 1 medium 50 total filings
· daily

US Merger & Acquisition SEC Filings — June 18, 2026

The 11 filings in this M&A digest reveal a bifurcated SPAC landscape: while newly-formed blank-check companies like AmperCap and Keystone are successfully raising capital and enabling unit separation, a cluster of older SPACs (PHP Ventures, Bayview, Digital Asset Acquisition) are burning through extension deposits and facing existential deadlines. The most material event is the court-approved Chapter 11 sale of Twin Hospitality Group's parent (Fat Brands) to FBG Bid Co., with a $44M backup bid for Round Table Pizza, signaling distressed asset liquidation. Insider activity is minimal, but the mass resignation of M3-Brigade's entire board and C-suite (replaced by CC Capital executives) hints at a strategic pivot or pending deal. Period-over-period trends are sparse due to the pre-revenue nature of SPACs, but the aggregate data shows a clear pattern: 4 of 11 filings involve deadline extensions or redemption mechanics, indicating that the SPAC market's 'use-it-or-lose-it' pressure is intensifying. The most actionable intelligence lies in the non-redemption warrant structure at Digital Asset Acquisition, which creates a unique arbitrage opportunity for shareholders who hold through the merger.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — June 18, 2026

This overnight filing batch is dominated by insider trading activity, with over 35 Form 4 filings revealing a concentrated cluster of high-level selling at electronics manufacturing services firms (Celestica, Flex) and Bloom Energy. Period-over-period comparisons are not directly available in these filings, but the sheer volume and dollar amounts—nearly $20M in aggregate insider sales from just three companies—create a significant signal that warrants attention. Conversely, a few bright spots emerge: a CFO at Canaan Inc. made a small insider purchase, a director at Franklin BSP Realty Trust aggressively bought both common and preferred shares, and an IAC filing shows uniform director RSU conversions, indicating routine equity compensation rather than a sentiment shift. A material Schedule 13D/A from Magnetar Financial in Comtech reveals a deep financial restructuring with suspended covenants and high interest rates (16-18%), signaling distress. The Lesaka Technologies SC 13D/A shows persistent institutional selling by IFC affiliates over three months at declining prices. The filing batch also includes a minor IPO-related registration for Kardigan, Inc. and a passive stake disclosure in Sound Group. Overall, the market receives a bearish tilt from the concentrated insider selling, offset by isolated bullish insider buying and neutral corporate actions.

43 high priority 7 medium 50 total filings
· daily

Biotech Small-Cap Approvals — June 17, 2026

The June 17, 2026 digest contains four biosimilar approvals, all classified as FALLBACK type and neutral signals, with zero NMEs or label expansions. The approvals span neurology (LACOSAMIDE, PERAMPANEL), diagnostic imaging (GADOBUTROL), and oncology (TRETINOIN), indicating no dominant therapeutic area theme. The highest-conviction signal is the approval of LACOSAMIDE by PROD DEVELOPMENT and PERAMPANEL by TARO, which modestly expands their generic CNS portfolios but lacks disclosed commercial data to assess peak sales or market share impact. Key risk is the absence of NME or breakthrough therapy approvals, signaling a slow innovation period for small-cap biotechs, and the neutral signals across all approvals suggest limited near-term investment catalysts.

4 total filings
· daily

Big Pharma Approvals — June 17, 2026

This digest covers two FDA approvals from June 12, 2026, both classified as 'Other' (non-NME, non-biosimilar, non-label expansion), with a bullish signal mix of 2-0-0. The dominant theme is a mixed-signal day: AbbVie Inc. secured a label expansion for its blockbuster IL-23 inhibitor risankizumab (SKYRIZI), while Bayer HealthCare Pharmaceuticals received an NME approval for an undisclosed Orphan Drug. The highest-conviction signal is Bayer's NME approval, given the 8/10 strength and materiality score and the Orphan Drug designation, which typically confers 7-year market exclusivity and premium pricing potential. The key risk is the lack of disclosed commercial data (peak sales, exclusivity, pricing) for both approvals, limiting full investment thesis validation. Notably, the absence of biosimilar approvals and the single therapeutic area (undisclosed for Bayer) prevent a clear sector clustering signal.

2 total filings
· daily

Orphan Drug Approvals — June 17, 2026

This digest covers two FDA approvals on June 17, 2026, with a mix of zero NMEs, zero biosimilars, zero label expansions, and two 'Other' approvals. The dominant therapeutic area theme is not clearly defined due to one undisclosed drug. The highest-conviction signal is the undisclosed NME from BAYER HEALTHCARE PHARMS, which carries Orphan Drug designation and a strong bullish signal (8/10), suggesting a high-value, niche commercial opportunity. A key risk is the lack of commercial data (peak sales, exclusivity, pricing) for both approvals, limiting precise investment modeling. The ABBVIE INC label expansion for RISANKIZUMAB-RZAA (SKYRIZI) is a lower-conviction bullish signal (5/10), likely reflecting a modest market extension rather than a transformative catalyst.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — June 17, 2026

This digest covers a single $103.3 million civilian infrastructure contract awarded to Kiewit Infrastructure West Co. by the National Park Service for a wastewater treatment plant replacement in Yosemite National Park. The contract is entirely civilian (0% defense-related) and signals stable, long-duration investment in national park infrastructure, with full funding obligated at award providing clear revenue visibility. However, the firm-fixed-price structure transfers significant cost-overrun risk to Kiewit on a complex construction project, and the neutral signal strength (5/10) and low materiality (3/10) suggest limited near-term stock impact. The key risk is execution on a fixed-price, multi-year construction project in a remote, environmentally sensitive location.

1 total filings
· daily

Defense Manufacturing Contracts — June 17, 2026

This digest covers a single $309.6 million defense manufacturing contract, solely within the civilian Department of Transportation (Maritime Administration), not the DoD. TOTE SERVICES, LLC won a competitively awarded, firm-fixed-price delivery order for the NSMV V vessel, with 85% of the value already funded, significantly de-risking future payment exposure. The highest-conviction signal is revenue visibility for TOTE through August 2029, but the fixed-price structure introduces execution risk over the multi-year build. The key watch item is any cost overrun that could compress margins on this single-vessel program.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 17, 2026

The sole contract in this period is a $126.4M cost-plus-fixed-fee delivery order awarded to Leidos Holdings, Inc. by the NIH National Cancer Institute for GOCO R&D facility space management in Frederick, MD. This is a purely civilian, non-defense award, reinforcing Leidos' entrenched position in federal life sciences R&D support. The neutral signal (strength 6/10, materiality 4/10) reflects stable, low-risk revenue but limited upside due to the cost-plus pricing structure and a fixed end date in August 2024. Key risks include NIH budget appropriation uncertainty for FY2024 and the absence of options for extension, which could create a revenue gap for Leidos' health segment.

1 total filings
· daily

New Federal Contractors — June 17, 2026

The three contracts awarded between June 17, 2026, and June 17, 2026, total $539.3 million in obligations, with only one-third defense-related, signaling a civilian-heavy procurement week. The dominant theme is infrastructure and facility management, led by a $309.6 million Maritime Administration shipbuilding award to TOTE Services (85% already funded) and a $103.3 million National Park Service wastewater plant replacement to Kiewit Infrastructure West. The highest-conviction signal is the TOTE contract, offering multi-year revenue visibility but carrying fixed-price execution risk through 2029. A key risk is Kiewit's high pricing risk on a complex fixed-price construction project, which could compress margins if cost overruns emerge.

3 total filings
· daily

Significant Contract Modifications ($10M+) — June 17, 2026

The $539.3 million in significant contract modifications from June 17, 2026, is heavily weighted toward a single civilian award: TOTE SERVICES, LLC's $309.6 million firm-fixed-price delivery order from the Maritime Administration for the NSMV V vessel, which is 85% funded and provides multi-year revenue visibility through 2029. Only one of the three contracts is defense-related (Leidos Biomedical Research's $126.4 million NIH NCI GOCO facility management award), underscoring a civilian infrastructure and life sciences R&D theme rather than a defense spending surge. The highest-conviction signal is the TOTE award, which is bullish due to its high funding outlay and stable shipbuilding demand, but carries medium execution risk from the fixed-price structure. Key risks include Kiewit Infrastructure West's $103.3 million Yosemite wastewater plant contract, which is fully obligated but high-risk due to fixed-price construction exposure, and the lack of any defense-related growth catalyst in this batch.

3 total filings
· daily

Contract Deobligations Alert — June 17, 2026

The June 17, 2026 contract deobligations digest totals $539.3 million, with 1 of 3 contracts defense-related (TOTE Services' $309.6M vessel award), reflecting a civilian-heavy mix. The highest-conviction signal is TOTE Services' fully funded firm-fixed-price delivery order for the NSMV V vessel, which provides 85% funded revenue visibility through 2029 but carries fixed-price execution risk. A key watch item is Kiewit Infrastructure West Co.'s $103.3M National Park Service wastewater treatment plant contract, which is fully obligated at award but carries high execution risk due to its fixed-price nature and long duration. The digest reveals a pattern of large, non-small businesses winning competitively awarded contracts across civilian agencies (Transportation, HHS, Interior), with no sole-source or set-aside signals, indicating a neutral-to-bullish environment for established contractors in shipbuilding, life sciences R&D, and civil infrastructure.

3 total filings
· daily

Contract Option Exercises — June 17, 2026

The June 17, 2026 contract option exercise stream totals $539.3 million in obligations, with only one-third defense-related, reflecting a civilian-heavy mix led by the Department of Transportation's Maritime Administration. The highest-conviction signal is TOTE Services' $309.6 million firm-fixed-price award for NSMV V vessel construction, which is 85% funded and provides multi-year revenue visibility but carries fixed-price execution risk through 2029. Leidos Biomedical Research's $126.4 million NIH NCI facility management contract offers stable, low-risk cost-plus revenue but has limited upside as it expires in August 2024. Kiewit Infrastructure's $103.3 million Yosemite wastewater plant contract is fully obligated but carries high execution risk due to its fixed-price structure and long duration. Key watch items include TOTE's ability to deliver on budget and potential follow-on NSMV contracts from the Maritime Administration.

3 total filings
· daily

All HHS Contracts — June 17, 2026

The sole HHS contract analyzed, a $126.4M cost-plus-fixed-fee delivery order awarded to Leidos Holdings, Inc. by the NIH National Cancer Institute, represents a stable, low-risk civilian revenue stream for the company through August 2024. The contract, won under full-and-open competition, reinforces Leidos' entrenched position in federal life sciences R&D facility management, but its fixed end date and lack of options limit upside. With $74.2M already outlayed, approximately $52.2M remains in obligated funding, providing near-term visibility. The key risk is the absence of a follow-on award or extension, which could create a revenue gap for Leidos' biomedical research segment. No defense-related contracts were identified in this period, underscoring a purely civilian healthcare R&D theme.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — June 17, 2026

The three contracts totaling $539.3 million are overwhelmingly civilian, with only one-third defense-related (the TOTE Services shipbuilding award) and the remainder split between Leidos' NIH facility management and Kiewit's National Park Service infrastructure work. The strongest investment signal is the $309.6 million TOTE Services vessel contract, which is 85% funded already and provides multi-year revenue visibility, though the firm-fixed-price structure introduces execution risk over a multi-year build. The Leidos contract is a low-risk, cost-plus R&D support award, but the 2019 award date and partial funding limit forward visibility. The Kiewit wastewater plant contract carries high fixed-price execution risk on a complex build. Key watch items include TOTE's cost performance on the NSMV V vessel and potential for follow-on Maritime Administration contracts.

3 total filings